Abstract: A process for the preparation of biologically active somatotropin from inclusion bodies of a recombinant host cell containing an inactive form of said somatotropin protein comprises the steps of: (a) contacting the inclusion bodies with an aqueous alcohol solution at an alkaline pH to solubilize said protein; and (b) bringing the solubilized protein into contact with a mild oxidizing agent to refold and form intramolecular disulfide bonds between cysteine residues of said protein.

Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

Abstract: Polypeptides with sequence corresponding or homologous to that of endostatin, having inhibiting activity on angiogenesis, are useful in the treatment of angiogenesis-dependent tumors.

Abstract: Compounds of formula (I): wherein B, X, R3, R21, R22, R1 and Rc are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Abstract: Methods for synthesizing proinsulin polypeptides are described that include a contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also described as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates are also described.

Abstract: The invention provides compounds of formula Wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R6e and R7 are defined in the specification. These compounds are useful as antibiotic agents.

Abstract: Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

Abstract: Disclosed herein are novel pharmaceutical agents and compositions, as well as novel methods, to enhance the absorption of polypeptide drug substances that normally display little if any absorbability if administered orally. Also disclosed are novel compositions and methods to significantly enhance the bioavailability and pharmacological efficacy of polypeptide drug substances whether administered orally or parenterally.

Abstract: Compounds of formula (I): wherein B, Y, R3, R24, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Abstract: The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.

Abstract: The present invention relates to cyclic peptides as inhibitors of urokinase binding to the urokinase receptor. Said cyclic peptides are suitable as pharmaceutical active substances for disorders mediated by urokinase and its receptor.

Abstract: The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.

Abstract: A method for producing a modified glutenin or seed-storage protein, the method comprising adding to the protein an exogenous amino acid domain which confers to the modified protein the ability to bind a ligand or other macromolecule. Wherein the modified protein has an ability to incorporate into gluten, modified glutenin or seed-storage proteins, and uses thereof.

Abstract: Peptides which can induce specific CTLs for HIV, DNAs encoding for the peptides and medicaments for preventing and/or treating HIV comprising the peptides are provided. According to the present invention, peptides carrying novel CTL epitopes derived from HIV Pol or Env proteins are provided. These peptides can bind to HLA-A11, particularly HLA-A*1101 which is frequently encountered in Japanese people and induce HIV-specific cytotoxic T cells.

Abstract: A human prolactin-binding protein and compositions and methods using this protein are provided.

Abstract: This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average IDS). Then the administration of the bisphosphonate preparation is interruption in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bisphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again.

Abstract: The present invention relates to compounds that are capable of modulating CD154 mobilization and that are useful for stabilizing the thrombotic process and reducing the activation of cells involved in an inflammatory response. The present invention also relates to methods useful for identifying such compounds. The present invention also relates to the treatment of platelets for transfusion with metalloproteinase inhibitors to treat or prevent inflammation. The present invention also includes compositions and methods to treat injury and disease related to such biological processes.

Abstract: Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

Abstract: The use of Colostrinin as a medicament, particularly in the treatment of chronic disorders of the central nervous system and the immune system.

Abstract: An antimicrobial composition and more particularly a germicidal spray for sanitizing and disinfecting surfaces including leather, wood, metal, plastic and fabric, comprises a mixture of essential oils capable of being dissolved or dispersed by a solvent in a water carrier, oils and an ionizing agent such as Blue Stone ions which speeds up the antimicrobial activity of the essential oils. The product of the invention is completely natural and non-toxic to adults and children even if swallowed.